New and recently funded Medical Startups
1
Country: China | Funding: $406M
Angitia Biopharmaceuticals develops therapies for the treatment of serious musculoskeletal disorders. It's currently conducting clinical trials of three biologic drug candidates for the treatment of osteoporosis, osteogenesis imperfecta (OI) and spinal fusion. Its flagship candidates are bispecific antibodies targeting sclerostin and DKK1, key negative regulators of Wnt signaling in bone tissue. Neutralization of sclerostin and DKK1 can stimulate bone formation and inhibit bone resorption. Together, these mechanisms may lead to increased bone mineral density.
Angitia Biopharmaceuticals develops therapies for the treatment of serious musculoskeletal disorders. It's currently conducting clinical trials of three biologic drug candidates for the treatment of osteoporosis, osteogenesis imperfecta (OI) and spinal fusion. Its flagship candidates are bispecific antibodies targeting sclerostin and DKK1, key negative regulators of Wnt signaling in bone tissue. Neutralization of sclerostin and DKK1 can stimulate bone formation and inhibit bone resorption. Together, these mechanisms may lead to increased bone mineral density.
2
Country: USA | Funding: $71.6M
Alaffia Health develops AI software for claims management in the healthcare industry. It uses AI agents to assist with clinical workflows, including case analysis. The company also provides AI designed for pre-processing clinical claims and medical records, routing claims based on complexity and cost, generating clinical summaries and supporting physician review of decisions. The company's primary goal is to create AI that is explainable and trusted by physicians, operators, and regulators, bringing transparency and clinical accuracy to claims processing. The system also helps reduce insurance costs for employers who self-insure.
Alaffia Health develops AI software for claims management in the healthcare industry. It uses AI agents to assist with clinical workflows, including case analysis. The company also provides AI designed for pre-processing clinical claims and medical records, routing claims based on complexity and cost, generating clinical summaries and supporting physician review of decisions. The company's primary goal is to create AI that is explainable and trusted by physicians, operators, and regulators, bringing transparency and clinical accuracy to claims processing. The system also helps reduce insurance costs for employers who self-insure.
3
Country: South Korea | Funding: ₩27B
Aston Sci develops cancer vaccines based on mRNA, DNA and peptides, which are currently being evaluated for efficacy in breast and gastric cancer. The company has created a cloud-based Collaborative Drug Discovery platform, powered by the Th-Vac AI epitope screening system and supported by an antigen-based epitope prediction program. Using the platform's results, the company performs precise immunological screening, enabling the identification of highly selective epitopes specific to MHC class II, known for their ability to induce strong and sustained CD4⁺ T-cell immunity. By integrating multi-omics datasets with machine learning, Th-Vac overcomes key barriers in the development of off-the-shelf vaccines encoding TAAs (tumor-associated antigens) or TCAs (tumor-specific antigens), as well as personalized neoantigen vaccines, including tumor heterogeneity, lengthy manufacturing lead times, and limited patient applicability.
Aston Sci develops cancer vaccines based on mRNA, DNA and peptides, which are currently being evaluated for efficacy in breast and gastric cancer. The company has created a cloud-based Collaborative Drug Discovery platform, powered by the Th-Vac AI epitope screening system and supported by an antigen-based epitope prediction program. Using the platform's results, the company performs precise immunological screening, enabling the identification of highly selective epitopes specific to MHC class II, known for their ability to induce strong and sustained CD4⁺ T-cell immunity. By integrating multi-omics datasets with machine learning, Th-Vac overcomes key barriers in the development of off-the-shelf vaccines encoding TAAs (tumor-associated antigens) or TCAs (tumor-specific antigens), as well as personalized neoantigen vaccines, including tumor heterogeneity, lengthy manufacturing lead times, and limited patient applicability.
4
Country: Japan | Funding: ¥13.6B
AI Medical Service develops AI-based software and device to support endoscopic imaging of the stomach and detect gastric cancer. The company has already received certification (in Japan) for its AI-based endoscopic detection add-on device, which operates inside the stomach. The AI system analyzes endoscopic images of the stomach obtained by endoscopic equipment during an endoscopic examination. The device then detects areas in the images suspicious for early gastric adenoma and assists physicians in diagnosing these lesions by placing a frame within the image and playing a sound. These mechanisms help the observer to focuse attention, interpret the image and detect lesions.
AI Medical Service develops AI-based software and device to support endoscopic imaging of the stomach and detect gastric cancer. The company has already received certification (in Japan) for its AI-based endoscopic detection add-on device, which operates inside the stomach. The AI system analyzes endoscopic images of the stomach obtained by endoscopic equipment during an endoscopic examination. The device then detects areas in the images suspicious for early gastric adenoma and assists physicians in diagnosing these lesions by placing a frame within the image and playing a sound. These mechanisms help the observer to focuse attention, interpret the image and detect lesions.
5
Country: USA | Funding: $335.4M
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
6
Country: USA | Funding: $1.1B
Treeline Biosciences develops oral small molecules for precision treatment of cancer. It also creates protein splitters and "stickers" for situations where traditional small molecules are unlikely to be effective, focusing on pharmacology from the outset. For drug delivery, the company uses antibody-tagged conjugates (TT-ADCs), an elegant solution that avoids exposure to healthy tissues. Treeline is conducting clinical trials of two drugs for the treatment of lymphoma: TLN-121 (in-house developed), which disrupts the BCL6 protein, and TLN-254 (licensed from Hengrui Pharmaceuticals), which inhibits the EZH2 protein. The company has also begun clinical trials of a pan-KRAS inhibitor, TLN-372, for the treatment of solid tumors with certain KRAS mutations.
Treeline Biosciences develops oral small molecules for precision treatment of cancer. It also creates protein splitters and "stickers" for situations where traditional small molecules are unlikely to be effective, focusing on pharmacology from the outset. For drug delivery, the company uses antibody-tagged conjugates (TT-ADCs), an elegant solution that avoids exposure to healthy tissues. Treeline is conducting clinical trials of two drugs for the treatment of lymphoma: TLN-121 (in-house developed), which disrupts the BCL6 protein, and TLN-254 (licensed from Hengrui Pharmaceuticals), which inhibits the EZH2 protein. The company has also begun clinical trials of a pan-KRAS inhibitor, TLN-372, for the treatment of solid tumors with certain KRAS mutations.
7
Country: USA | Funding: $2.6M
Kovina Therapeutics is a preclinical biotechnology company developing a unique antiviral drug for the treatment of cancer and precancerous conditions associated with the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers. The company used powerful biotechnological tools to study the molecular mechanisms by which HPV proteins control infected cells and discovered new therapeutic molecules that block viral activity. The developed therapy should provide a non-surgical treatment option for HPV-induced cancer and precancerous conditions. This small-molecule drug specifically targets the HPV E6 oncogene, an oncogenic factor expressed in both precancerous and cancerous tissues. By inactivating HPV E6, the drug triggers apoptosis in infected cells without affecting healthy tissue.
Kovina Therapeutics is a preclinical biotechnology company developing a unique antiviral drug for the treatment of cancer and precancerous conditions associated with the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers. The company used powerful biotechnological tools to study the molecular mechanisms by which HPV proteins control infected cells and discovered new therapeutic molecules that block viral activity. The developed therapy should provide a non-surgical treatment option for HPV-induced cancer and precancerous conditions. This small-molecule drug specifically targets the HPV E6 oncogene, an oncogenic factor expressed in both precancerous and cancerous tissues. By inactivating HPV E6, the drug triggers apoptosis in infected cells without affecting healthy tissue.
8
Country: Canada
Wema is developing mobile app and online platform that provides cervical cancer screening to those in remote communities. It enables access to oncology services to those in need who currently have limited access to mainstream healthcare. The platform also offers high-quality provider and mentor training, real-time data collection and report writing. This allows rural healthcare workers to enhance their skills in conducting high-quality screening with real-time mentoring and diagnosis confirmation through a closed user group with colleagues and experts.
Wema is developing mobile app and online platform that provides cervical cancer screening to those in remote communities. It enables access to oncology services to those in need who currently have limited access to mainstream healthcare. The platform also offers high-quality provider and mentor training, real-time data collection and report writing. This allows rural healthcare workers to enhance their skills in conducting high-quality screening with real-time mentoring and diagnosis confirmation through a closed user group with colleagues and experts.
9
Country: USA | Funding: $2.6M
Ananya Health is developing a medical device for the treatment of precancerous cervical conditions. Unlike current cryoablation treatments, which rely on a complex supply chain of expensive, bulky and difficult-to-transport gas cylinders or require the involvement of specialists such as obstetricians and gynecologists, Ananya produces a portable, easy-to-use, closed-loop cryoablation platform called the CRCL, which can be used in any clinic. The system is battery-powered and has wheels for portability. The company also claims the procedure costs 1/10th the cost of traditional gas-based cryoablation.
Ananya Health is developing a medical device for the treatment of precancerous cervical conditions. Unlike current cryoablation treatments, which rely on a complex supply chain of expensive, bulky and difficult-to-transport gas cylinders or require the involvement of specialists such as obstetricians and gynecologists, Ananya produces a portable, easy-to-use, closed-loop cryoablation platform called the CRCL, which can be used in any clinic. The system is battery-powered and has wheels for portability. The company also claims the procedure costs 1/10th the cost of traditional gas-based cryoablation.
10
Country: USA | Funding: $18.8M
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
